According to Fortune Business Insights, the global cell therapy market size was valued at USD 8.64 billion in 2025. The market is projected to grow from USD 12.22 billion in 2026 to USD 122.87 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 33.14% during the forecast period of 2026–2034. North America dominated the market with a 47.10% share in 2025, supported by established healthcare infrastructure, extensive research and development activities, and the availability of commercially approved cell-based treatments.
Market Overview
The cell therapy market is experiencing significant expansion as healthcare providers increasingly explore advanced treatments for diseases that have limited therapeutic options. Commercially available products, particularly chimeric antigen receptor T-cell (CAR-T) therapies, have established an important foundation for market growth.
According to Fortune Business Insights, the CAR-T cell therapy segment accounted for 99.8% of the market share in 2025. Its leadership reflects increasing clinical adoption, a strong product pipeline, and continued investment in engineered cellular treatments. Oncology remains the principal application area, while hospitals and clinics represent the leading end-user segment.
However, the market faces several challenges, including high treatment costs, complex manufacturing processes, patient-specific production requirements, and potential safety complications. Addressing these barriers will be essential for expanding access and supporting sustainable long-term growth.
For detailed market insights: https://www.fortunebusinessinsights.com/cell-therapy-market-114224
Market Trends
Expanding Applications Beyond Hematological Cancers
One of the major trends in the cell therapy market is the expansion of research beyond blood cancers into solid tumors. Companies are developing engineered T-cell therapies designed to recognize specific tumor-associated targets and address challenges such as cancer-cell resistance and antigen escape.
The U.S. Food and Drug Administration's approval of AMTAGVI (lifileucel) in February 2024 for advanced melanoma demonstrated progress in cellular immunotherapy for solid tumors. Such developments are encouraging further research into new cancer indications.
Growing Interest in Allogeneic Cell Therapies
Allogeneic cell therapies use cells obtained from donors rather than collecting and modifying each patient's own cells. These treatments may support more standardized manufacturing, improved scalability, and faster treatment availability.
Researchers and biotechnology companies are investigating donor-derived cellular platforms to reduce production complexity and potentially lower costs. Continued clinical development and advances in genetic engineering could strengthen the commercial prospects of these therapies.
Increasing Investment in Advanced Manufacturing
Cell therapies require specialized production, quality control, storage, and distribution systems. Consequently, companies are investing in advanced manufacturing facilities and collaborative development infrastructure to improve production efficiency and support commercialization.
Market Drivers
High Unmet Medical Needs in Oncology and Rare Diseases
The need for more effective treatments for cancer and rare diseases is a major driver of market growth. Cell therapies can provide targeted treatment options for patients whose conditions have not responded adequately to conventional approaches. Their potential for durable clinical responses has increased interest among healthcare professionals, researchers, and pharmaceutical companies.
Expanding Regulatory Approvals
Regulatory approvals and accelerated development pathways are helping promising cellular treatments reach eligible patients. New product approvals and expansions into additional indications can increase treatment availability and strengthen commercial opportunities.
Rising Research Investment and Strategic Collaborations
Pharmaceutical companies, biotechnology firms, academic institutions, and research organizations are investing in cellular engineering and clinical development. Partnerships can support technology sharing, manufacturing capabilities, and clinical research, helping companies advance innovative treatments through development and commercialization.
Market Segmentation
The cell therapy market is segmented by therapy type, product, indication, end user, and geography.
By Therapy Type: The market includes CAR-T cell therapy, T-cell receptor (TCR-T) cell therapy, natural killer (NK) cells, and other therapies. CAR-T cell therapy dominated in 2025, supported by commercial adoption, regulatory approvals, and an established clinical pipeline.
By Product: Key products include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and others. Yescarta held the leading position in 2025, benefiting from its approved indications, patient reach, and distribution network.
By Indication: The market is divided into oncology and other indications. Oncology represents the principal segment because of the availability of approved cancer cell therapies and continued investment in cancer-focused clinical development.
By End User: The market comprises hospitals and clinics, specialty clinics, and other end users. Hospitals and clinics accounted for 55.8% of the market in 2025 because they offer specialized infrastructure, multidisciplinary medical teams, and the monitoring required for treatment administration.
Key Players
Major companies operating in the cell therapy market include:
Novartis AG
Gilead Sciences, Inc.
Bristol Myers Squibb Company
Johnson & Johnson
Vertex Pharmaceuticals Incorporated
Bayer AG
F. Hoffmann-La Roche Ltd
Adaptimmune
Iovance Biotherapeutics, Inc.
Fate Therapeutics
These companies are strengthening their market positions through product development, clinical research, strategic partnerships, and investments in advanced treatment platforms.
Regional Analysis
North America
North America held the largest regional share at 47.10% in 2025, with a market valuation of USD 4.07 billion. The United States accounted for USD 3.79 billion. The region benefits from established biotechnology infrastructure, commercialized cell therapy products, research investment, and supportive reimbursement frameworks.
Europe
Europe represented the second-largest regional market, valued at USD 2.28 billion in 2025. The region is projected to register a CAGR of 30.80% during the forecast period. Research activity, clinical adoption, and regulatory developments are supporting growth in countries such as Germany, the U.K., and France.
Asia Pacific
Asia Pacific reached USD 1.39 billion in 2025, making it the third-largest regional market. China accounted for USD 0.50 billion, while India reached USD 0.08 billion. Increasing clinical capabilities, investment in biotechnology, and the introduction of locally developed treatments are contributing to regional development.
Latin America and the Middle East & Africa
Latin America was valued at USD 0.47 billion in 2025. Meanwhile, the Gulf Cooperation Council (GCC) market reached USD 0.24 billion. Adoption in these regions remains comparatively constrained by treatment affordability, specialized infrastructure requirements, and access to advanced healthcare services.
Competitive Landscape
The cell therapy market has a semi-fragmented competitive structure, with established pharmaceutical companies operating alongside emerging biotechnology firms. Leading companies benefit from commercial product portfolios, research capabilities, and established relationships with treatment centers.
Competition increasingly centers on developing therapies for additional cancer indications, improving treatment effectiveness, strengthening manufacturing capacity, and advancing allogeneic platforms. Collaborations, licensing agreements, clinical partnerships, and regulatory milestones are important strategies for expanding market presence.
For example, in June 2025, Bristol Myers Squibb announced U.S. FDA approvals involving Abecma for multiple myeloma and Breyanzi for large B-cell lymphoma and other lymphomas. Such developments illustrate the continuing evolution of commercially available cellular treatments.
Future Outlook
The cell therapy market is expected to experience substantial growth through 2034 as research advances and more treatments progress through clinical development. Continued innovation in CAR-T, TCR-T, natural killer cells, and donor-derived therapies could broaden the range of conditions addressed by cellular medicine.
Manufacturing improvements may help increase production capacity and improve treatment availability. Nevertheless, the industry's long-term expansion will depend on addressing safety risks, reducing treatment costs, strengthening reimbursement arrangements, and ensuring access to specialized treatment centers.
As regulatory approvals expand and clinical evidence develops, cell therapy is likely to remain an important component of precision medicine and advanced cancer treatment.
Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cell-therapy-market-114224
Conclusion
The global cell therapy market is positioned for rapid expansion, rising from USD 8.64 billion in 2025 to a projected USD 122.87 billion by 2034. Strong demand for advanced cancer treatments, growing research investment, and expanding regulatory approvals are supporting this growth. North America currently leads the market, while Europe and Asia Pacific offer further opportunities. Continued progress in manufacturing, affordability, and clinical development will be essential to unlocking the industry's long-term potential.
Frequently Asked Questions (FAQs)
1. What is the global cell therapy market size?
According to Fortune Business Insights, the global cell therapy market was valued at USD 8.64 billion in 2025 and is projected to reach USD 122.87 billion by 2034.
2. What is the expected CAGR of the cell therapy market?
The market is projected to grow at a CAGR of 33.14% during the forecast period of 2026–2034.
3. Which region dominates the cell therapy market?
North America dominated the global market with a 47.10% share in 2025, supported by established healthcare infrastructure, research investment, and commercial treatment availability.
4. Which therapy type leads the cell therapy market?
CAR-T cell therapy was the leading therapy type in 2025, accounting for 99.8% of the market share.
5. Who are the major players in the cell therapy market?
Key companies include Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Vertex Pharmaceuticals Incorporated, Iovance Biotherapeutics, and Adaptimmune.
What’s Driving Japan’s Market? Discover the Latest Cell Therapy Market Insights